Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.42 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843909 | 1.00 | GGT1 (0.42) | GGT1ARG1ARG2ACLYBLM | |
| SCHEMBL909828 | 1.00 | GGT1 (0.42) | GGT1ARG1ARG2ACLYBLM | |
| SCHEMBL27626186 | 1.00 | GGT1 (0.42) | GGT1ARG1ARG2ACLYBLM | |
| SCHEMBL6060538 | 1.00 | GGT1 (0.42) | GGT1ARG1ARG2ACLYBLM | |
| SCHEMBL120903 | 1.00 | GGT1 (0.42) | GGT1ARG1ARG2ACLYBLM | |
| SCHEMBL909829 | 1.00 | GGT1 (0.42) | GGT1ARG1ARG2ACLYBLM | |
| Hydrochloric Acid SCHEMBL2713502 | 0.98 | GGT1 (0.41) | GGT1ARG1ARG2ACLYBLM | |
| Hydrochloric Acid SCHEMBL6193942 | 0.98 | GGT1 (0.41) | GGT1ARG1ARG2ACLYBLM | |
| Hydrochloric Acid SCHEMBL6193436 | 0.98 | GGT1 (0.41) | GGT1ARG1ARG2ACLYBLM | |
| SCHEMBL6194043 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534668-B1 | CRYSTALLINE SOLID FORM OF (2S-5Z)-2-AMINO-7-(ETHANIMIDOYLAMINO)-2-METHYLHEPT-5-ENOIC ACID | PHARMACIA CORP (US) | 2012-05-02 | — | — | EP | claimed |
| JP-4708024-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| US-6998503-B2 | Crystalline solid form of (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid | PHARMACIA CORPORATION (US) | 2006-02-14 | — | — | US | claimed |
| EP-1534668-A1 | CRYSTALLINE SOLID FORM OF (2S-5Z)-2-AMINO-7-(ETHANIMIDOYLAMINO)-2-METHYLHEPT-5-ENOIC ACID | Pharmacia Corporation (US) | 2005-06-01 | — | — | EP | claimed |
| US-20050113451-A1 | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION (US) | 2005-05-26 | — | — | US | claimed |
| EP-1317421-B1 | 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORP (US) | 2005-02-23 | — | — | EP | claimed |
| US-20040132822-A1 | Crystalline solid form of (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid | PHARMACIA LLC | 2004-07-08 | — | — | US | claimed |
| WO-2004018412-A1 | CRYSTALLINE SOLID FORM OF (2S-5Z)-2-AMINO-7-(ETHANIMIDOYLAMINO)-2-METHYLHEPT-5-ENOIC ACID | PHARMACIA CORPORATION (US) | 2004-03-04 | — | — | WO | claimed |
| EP-1317421-A1 | 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020132849-A1 | 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-09-19 | — | — | US | claimed |
| WO-2002022562-A1 | 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2002-03-21 | — | — | WO | claimed |
| US-20180214430-A1 | Selective Inhibitors Of i-NOS For Use Against Viral Infection | UCL BUSINESS PLC (GB) | 2018-08-02 | — | — | US | disclosed |
| EP-3019478-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015006280-A9 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015006280-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20040132822-A1 | Crystalline solid form of (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid | PHARMACIA LLC | 2004-07-08 | — | — | US | disclosed |
| WO-2004018412-A1 | CRYSTALLINE SOLID FORM OF (2S-5Z)-2-AMINO-7-(ETHANIMIDOYLAMINO)-2-METHYLHEPT-5-ENOIC ACID | PHARMACIA CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-1317421-A1 | 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020132849-A1 | 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-09-19 | — | — | US | disclosed |
| WO-2002022562-A1 | 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214430-A1 | Selective Inhibitors Of i-NOS For Use Against Viral Infection | NOS2, NOS1, NOS3 | GGT1 438/4885ARG1 80/4885ARG2 50/4885 |
| US-20040132822-A1 | Crystalline solid form of (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid | SLC7A5, SLC6A15, METTL14 | GGT1 3674/4885ARG1 2930/4885ARG2 3737/4885 |
| US-20020132849-A1 | 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PTGIS, ALOX5, ALOX15 | GGT1 803/4885ARG1 583/4885ARG2 275/4885 |
| US-20050113451-A1 | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PTGIS, ALOX5, ALOX15 | GGT1 803/4885ARG1 583/4885ARG2 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.